Abstract
Although included in the serological domain of the ‘interstitial pneumonia with auto-immune features’ (IPAF) research statement, the search for myositis-specific antibodies (MSA) is not incorporated in routine clinical practice. The objective of the study was to evaluate MSA prevalence in an idiopathic interstitial pneumonia (IIP) cohort (n = 68) with suggestive morphological interstitial lung disease patterns. Twelve of 68 patients (17.6%) carried MSA, whereof only two were anti-nuclear antibody-positive. Besides female gender, no demographic or pulmonary function parameter was predictive for MSA positivity. MSA were present in 32.4% of IPAF patients (n = 37), being essential for IPAF diagnosis in four of them (10.8%).
This is a preview of subscription content, log in via an institution to check access.
References
Kim H-C, Ji W, Kim MY, Colby TV, Jang SJ, Lee C-K, Han SB, Kim DS (2015) Interstitial pneumonia related to undifferentiated connective tissue disease. Chest 147:165–172
Fischer A, Antoniou KM, Brown KK et al (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987
Marie I, Hachulla E, Chérin P, Dominique S, Hatron P-Y, Hellot M-F, Devulder B, Herson S, Levesque H, Courtois H (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Care Res 47:614–622 (Hoboken)
Hamaguchi Y, Fujimoto M, Matsushita T et al (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. https://doi.org/10.1371/journal.pone.0060442
Lega J-C, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V (2015) Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 24:216–238
Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367–371
Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, Ryu JH (2001) Polymyositis–dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–1185
Karadimitrakis S, Plastiras SC, Zormpala A, Chatzikonstantinou K, Boki KA, Tzelepis GE, Moutsopoulos HM (2008) Chest CT findings in patients with inflammatory myopathy and Jo1 antibodies. Eur J Radiol 66:27–30
Chua F, Higton AM, Colebatch AN, O’reilly K, Grubnic S, Vlahos I, Edwards CJ, Kiely PDW (2012) Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology 51:1870–1876 (United Kingdom)
Plastiras SC, Soliotis FC, Vlachoyiannopoulos P, Tzelepis GE (2007) Interstitial lung disease in a patient with antisynthetase syndrome and no myositis. Clin Rheumatol 26:108–111
Tzelepis GE, Toya SP, Moutsopoulos HM (2008) Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 31:11–20
Travis WD, Costabel U, Hansell DM et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748
Garner R, Kumari R, Lanyon P, Doherty M, Zhang W (2015) Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 5:e006389
Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, Kawano S, Kumagai S (2008) Prevalence of disease-specific antinuclear antibodies in general population: Estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol 18:153–160
Fish EN (2008) The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 8:737–744
Acknowledgements
We thank the patients who participated in this study for providing serum samples for the biobank. We also thank Alphadia, Wavre, Belgium for the free disposal of the Myositis 12 IgG DOT for BlueDiver Instrument. We thank Doreen Dillaerts for expert technical assistance.
Funding
Research reported in this publication was supported by the Research Foundation—Flanders and the University Hospitals Leuven (1.8.325.12N). The funding sources were not involved in study design, data collection, data analysis, data interpretation, manuscript writing or the decision to submit the article for publication.
Author information
Authors and Affiliations
Contributions
LDS, EDL, XB and WW designed the study. XB performed the experiments. LDS wrote the manuscript. All authors reviewed and approved the content of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Dr De Sadeleer reports non-financial support from Roche and Boehringer Ingelheim, outside the submitted work. Prof Dr Wuyts reports grants from Roche, grants from Boehringer Ingelheim, grants from Research Foundation—Flanders, grants from National Institute of Health, outside the submitted work. Prof De Langhe and Prof Bossuyt have nothing to disclose. Mr Vigneron and Mr Bodart are employees of D-tek.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
De Sadeleer, L.J., De Langhe, E., Bodart, N. et al. Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias. Lung 196, 329–333 (2018). https://doi.org/10.1007/s00408-018-0108-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-018-0108-8